Objectives Drug product performance in patients with gastrointestinal (GI) diseases can be altered compared to healthy subjects due to pathophysiological changes. In this review, relevant differences in patients with inflammatory bowel diseases, coeliac disease, irritable bowel syndrome and short bowel syndrome are discussed and possible in vitro and in silico tools to predict drug product performance in this patient population are assessed. Key findings Drug product performance was altered in patients with GI diseases compared to healthy subjects, as assessed in a limited number of studies for some drugs. Underlying causes can be observed pathophysiological alterations such as the differences in GI transit time, the composition of the GI fluids and GI permeability. Additionally, alterations in the abundance of metabolising enzymes and transporter systems were observed. The effect of the GI diseases on each parameter is not always evident as it may depend on the location and the state of the disease. The impact of the pathophysiological change on drug bioavailability depends on the physicochemical characteristics of the drug, the pharmaceutical formulation and drug metabolism. In vitro and in silico methods to predict drug product performance in patients with GI diseases are currently limited but could be a useful tool to improve drug therapy. Summary Development of suitable in vitro dissolution and in silico models for patients with GI diseases can improve their drug therapy. The likeliness of the models to provide accurate predictions depends on the knowledge of pathophysiological alterations, and thus, further assessment of physiological differences is essential.
Objectives Drugs used to treat gastrointestinal diseases (GI drugs) are widely used either as prescription or over-the-counter (OTC) medications and belong to both the 10 most prescribed and 10 most sold OTC medications worldwide. The objective of this review article is to discuss the most frequent interactions between GI and other drugs, including identification of the mechanisms behind these interactions, where possible.Key findings Current clinical practice shows that in many cases, these drugs are administered concomitantly with other drug products. Due to their metabolic properties and mechanisms of action, the drugs used to treat gastrointestinal diseases can change the pharmacokinetics of some coadministered drugs. In certain cases, these interactions can lead to failure of treatment or to the occurrence of serious adverse events. The mechanism of interaction depends highly on drug properties and differs among therapeutic categories. Understanding these interactions is essential to providing recommendations for optimal drug therapy. Summary Interactions with GI drugs are numerous and can be highly significant clinically in some cases. While alterations in bioavailability due to changes in solubility, dissolution rate, GI transit and metabolic interactions can be (for the most part) easily identified, interactions that are mediated through other mechanisms, such as permeability or microbiota, are less well-understood. Future work should focus on characterising these aspects.
The
aim of the study was to investigate the impact of Crohn’s
disease (CD) on the performance of a lipid-based formulation of ciprofloxacin
in a complex gastrointestinal simulator (TIM-1, TNO) and to compare
the luminal environment in terms of bile salt and lipid composition
in CD and healthy conditions. CD conditions were simulated in the
TIM-1 system with a reduced concentration of porcine pancreatin and
porcine bile. The bioaccessibility of ciprofloxacin was similar in
simulated CD and healthy conditions considering its extent as well
as its time course in the jejunum and ileum filtrate. Differences
were observed in terms of the luminal concentration of triglycerides,
monoglycerides, and fatty acids in the different TIM-1 compartments,
indicating a reduction and delay in the lipolysis of formulation excipients
in CD. The quantitative analysis of bile salts revealed higher concentrations
for healthy conditions (standard TIM-1 fasted-state protocol) in the
duodenum and jejunum TIM-1 compartments compared to published data
in human intestinal fluids of healthy subjects. The reduced concentrations
of bile salts in simulated CD conditions correspond to the levels
observed in human intestinal fluids of healthy subjects in the fasted
state.A lipidomics approach with ultra performance liquid chromatography
(UPLC)/mass spectrometry (MS) has proven to be a time-efficient method
to semiquantitatively analyze differences in fatty acid and bile salt
levels between healthy and CD conditions. The dynamic luminal environment
in CD and healthy conditions after administration of a lipid-based
formulation can be simulated using the TIM-1 system. For ciprofloxacin,
an altered luminal lipid composition had no impact on its performance
indicating a low risk of altered performance in CD patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.